Market News & Trends
PolTREG Identifies Promising Efficacy Biomarker for Type-1 Diabetes in Patients Treated With its Treg Therapy in Combination With Rituximab
PolTREG S.A. recemtly announced it has published data in International Immunopharmacology, which suggest that PD-1+ T-cells are a dependable biomarker for efficacy in pediatric early-onset…
Medigene AG Secures European Patent for its iM-TCR Technology
Medigene AG recently announced it has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor (iM-TCR) technology, which…
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development
Biora Therapeutics, Inc. recently shared additional positive interim results from the single-ascending dose (SAD) clinical trial of BT-600, which is a drug-device combination consisting of…
Biognosys & Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma & Precision Medicine Research
Biognosys and Alamar Biosciences, Inc. recently announced a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers. This collaboration brings…
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
Lipella Pharmaceuticals Inc. recently announced the US FDA has granted a Type C meeting request to discuss the company’s proposed Phase-2b clinical trial design for…
BioCorRx Pharmaceuticals Awarded New Patent for Novel Compound to Treat Pain, Depression & Schizophrenia
BioCorRx Inc. recently announced its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, has been granted a new patent by the United States Patent and…
OrganaBio Launches On-Demand GMP-Compliant Hematopoietic Stem Cell Source for Advanced Therapy Manufacturing
OrganaBio recently announced the launch of HematoPAC-HSC-CB-GMP, on-demand current good manufacturing practice (cGMP)-compliant CD34+ hematopoietic stem cells (HSCs) ethically derived from fresh human cord blood.…
Evaxion & Undisclosed Collaborator Announce Encouraging Results for Vaccine Antigens Against Staphylococcus Aureus Infection
Evaxion Biotech A/S recently announced the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from Evaxion’s preclinical EVX-B1 vaccine candidate…
Bio-Rad Launches First Ultrasensitive Multiplexed Digital PCR Assay for Breast Cancer Mutation Detection in Clinical Research
Bio-Rad Laboratories, Inc. recently announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ESR1 Mutation Detection Kit. The assay expands the…
Ocuphire Announces US Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
Ocuphire Pharma, Inc. recently announced the US commercial launch of RYZUMVI (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ: VTRS). Ocuphire has a global…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….